TraderMichael
Post 33172
"In April, Public Health England reported the results of a large study of COVID-19 transmission involving more than 365,000 households with a mix of vaccinated and unvaccinated members"
Interesting. Wasnt aware of this particular study.
So presumably you'll be getting your next covid jab then?
How many times have you had covid btw. I've had it at least twice as far as I am aware.
Zero Covid 19 vaccinations here. And I wont take the FLU vaccine either because they are going to make it a bivalent one(so you get Flu + Covid19 latest strain)
FYI I know of my several family members who have suffered "severe adverse events" post their 3rd Jab and will not take any more.
And as to excess deaths globally in countries with high vaccination rates.
Wonder that is all about.
Wil lwe ever get told the truth?
Decent news from GSK this morning has to be said. |
dplwise1 - that these claimants are settling like this indicates to me that the closer they get to a trial the weaker they feel their case is. Its likely that others will be deterred (and their ambulance-chasing lawyers) who are seeking mega-payouts rather than genuinely wanting to have their 'day in court' and are now prepared to take some money (and run).
There is no causal evidence that scientifically proves a direct link between Zantac itself and these unfortunate peoples' cancers. |
GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended expanding the approval of GSK’s respiratory syncytial virus (RSV) vaccine for the prevention of lower respiratory tract disease (LRTD) caused by RSV from adults aged 60 and above to include adults aged 50-59 years at increased risk for RSV disease.
Today’s positive opinion is the first time that an indication for adults aged 50-59 has been recommended by CHMP for a RSV vaccine, one of the final steps prior to the extension of the marketing authorisation by the European Commission. The European Commission’s final decision is expected by September 2024. Since June 2023, Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) has been approved in Europe for adults aged 60 and over for the prevention of RSV-LRTD. |
Zantac settlement with Ronald Kimbrow .. case now dismissed. Not a fan of this tbh I'm sure there are benefits to GSK but to the layman it just seems like as admission of guilt |
Nice to see a bounce off the 12 month TA support trend line at 1500, almost predictable.. :o), where to next..? the Zantac cases have not gone away, but oversold now down from the 1800 May high.. |
In April, Public Health England reported the results of a large study of COVID-19 transmission involving more than 365,000 households with a mix of vaccinated and unvaccinated members.
It found immunisation with either the Pfizer or AstraZeneca vaccine reduced the chance of onward virus transmission by 40-60%. This means that if someone became infected after being vaccinated, they were only around half as likely to pass their infection on to others compared to infected people who weren’t vaccinated. |
TraderMichael
There was never any evidence that the Covid vaccines prevented transmission but they were foisted on everyone who couldnt afford to say NO regardless.
Chance these jabs delay Dementia minimal.
All part of the sales gimmick to encourage uptake.
And NO I wont be taking my Flu vaccine annually either. |
Interesting that the study was not performed by GSK. Its hard to see the pathway on how it would work, but the data set is already substantial. I doubt it will ever be recommended as a prevention but it may increase the uptake of shingrix. There is a little more here |
But there's evidence:
Researchers compared some 100,000 people who had a new (GSK) shingles jab to a similar group who had an older one. On average, those who had the new jab had an extra 164 days free from a diagnosis of dementia over six years. Further work is needed to prove the link, scientists say. |
>>Stock price chart suggests the yanks are the ones trading on the short side here
Yes, that's quite likely, especially considering the problems are mostly caused by US ambulance chasers. |
Shingles could delay Dementia.
Yeah righto.
You're the last person I'd expect to fall for that speculative gusto |
Would be a big market... |
Second tranche added. Very unloved this stock isn't it |
Good data. Stock price chart suggests the yanks are the ones trading on the short side here |
 GSK PLC on Tuesday reported "positive" data for testing on three different treatments by ViiV Healthcare, its majority-owned specialist HIV company.
The London-based pharmaceutical company firstly said ViiV Healthcare has shared 48-week findings from the phase 4 Paso Doble clinical trial investigating the two-drug regimen Dovato compared with the three-drug regimen Biktarvy for HIV.
Dovato comprises dolutegravir and lamivudine, while the Biktarvy regimen consists of bictegravir, emtricitabine and tenofovir alafenamide fumarate.
The trial, GSK said, focused on patients "who are virologically suppressed and who could benefit from treatment optimisation".
The 48-week results showed that virologically suppressed adults with HIV, if they switched to the Dovato regimen, demonstrated non-inferior efficacy in maintaining viral suppression compared with switching to Biktarvy.
Secondly GSK said ViiV, in which Pfizer Inc and Shionogi & Co Ltd also hold minority interests, announced positive data for HIV drug Apretude, or cabotegravir LA for PrEP, in pregnant people.
The new maternal safety and pregnancy outcomes and pharmacokinetic findings came from the HIV Prevention Trials Network's 084 open label extension, which evaluated cisgender women in sub-Saharan Africa who became pregnant while using Apretude for HIV pre-exposure prophylaxis, or PrEP.
"The findings showed that [Apretude] was generally well tolerated among pregnant women, and PK findings demonstrated that cabotegravir levels were maintained above those associated with HIV protection throughout the overall pregnancy period," GSK said.
Finally, GSK and ViiV announced phase 1 study results and in vitro data for VH4524184 or VH184, an investigational integrase strand transfer inhibitor or INSTI.
ViiV, GSK said, shared positive in vitro findings showing that VH184 retained its antiviral activity and could be effective in countering second-generation INSTI resistance.
Analysis of the phase 1 study, meanwhile, showed that PK and safety data supported the further development of VH184.
"The study showed VH184 achieved drug levels in the blood that could potentially exhibit sufficient antiviral activity against the clinically derived INSTI mutations seen in vitro," GSK explained. |
Morgan Stanley cuts target price to 1800p from 1860p |
GlaxoSmithKline (GSK) has announced the European Medicines Agency’s acceptance of their marketing application for Blenrep, a treatment for relapsed or refractory multiple myeloma. Promising results from two phase III trials, DREAMM-7 and DREAMM-8, indicated significant improvements in progression-free survival when compared to standard care. If approved, Blenrep could notably change the treatment landscape for this challenging blood cancer. |
IN @ 1520.928 ...... ;0) |
Bought a first Tranche at a smidge under 1508p |
Looking to make a first ever purchase here, but it looks like we are going to have a long summer on the UK stock market based on the last week or so. Dreadful performance despite massive undervaluation everywhere |
Drugs giant GSK is set to move its global headquarters back to central London, ending more than two decades at its Brentford base.
Around 3,000 employees will work from The Earnshaw building on the corner of New Oxford Street from Tuesday.
It marks the end of its time at the Brentford site in west London after the £315 million building was officially opened in 2002 by then prime minister Tony Blair.
GSK’s new HQ will house the firm’s leadership team – headed by chief executive Dame Emma Walmsley – as well as units supporting research and development, supply chain, commercial operations, corporate functions and its ViiV Healthcare specialist HIV joint venture.
It sees GSK return to central London, where the company traces its roots back to the Plough Court Pharmacy, founded in the City in 1715.
GSK said on announcing the new global HQ in December 2022 that the six-floor building would be designed with hybrid working in mind, including technology to support remote working, while also aiming to be energy efficient to help meet the firm’s 2030 net zero goals.
Dame Emma said at the time: “We are proud to call London our home and look forward to the opportunities for even closer collaboration with the city’s world-class science, academic and healthcare institutions.” |
Aug 23rd .... FDA decision on Jemperli Ph 3 RUBY trial |
No! Very good. ;) |
Good day Alphorn
"GSK have anything for this huge market?"
==========================================
Was the pun intended? |
Register for streaming realtime charts, analysis tools, and prices.
Hot Features
Premium
